These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Withdrawal syndrome following long-term administration of tamoxifen. Kerr B; Myers P J Psychopharmacol; 1999 Dec; 13(4):419. PubMed ID: 10667620 [No Abstract] [Full Text] [Related]
3. Refractory Tamoxifen-Induced Keratopathy Despite Drug Withdrawal. Andreanos K; Oikonomakis K; Droutsas K; Petrelli M; Kymionis G Cornea; 2017 Mar; 36(3):377-378. PubMed ID: 27918356 [TBL] [Abstract][Full Text] [Related]
4. Tamoxifen withdrawal response. Report of a case. Belani CP; Pearl P; Whitley NO; Aisner J Arch Intern Med; 1989 Feb; 149(2):449-50. PubMed ID: 2537066 [TBL] [Abstract][Full Text] [Related]
5. Tamoxifen and hypercalcaemia. A case report. Bezwoda WR; Derman D; Zaltzman M; de Moor NG; Lange M S Afr Med J; 1980 Nov; 58(20):821-2. PubMed ID: 6255614 [TBL] [Abstract][Full Text] [Related]
7. Stopping tamoxifen after 5 years of therapy for early breast cancer: does it alter quality of life? Hall PS; Walkington JP; Cameron DA Clin Oncol (R Coll Radiol); 2011 Nov; 23(9):652. PubMed ID: 21703830 [No Abstract] [Full Text] [Related]
8. Ovarian hyperstimulation syndrome in a patient treated with tamoxifen for breast cancer. Cohen I Fertil Steril; 2011 Sep; 96(3):e147; author reply e148. PubMed ID: 21762898 [No Abstract] [Full Text] [Related]
9. [Histological analysis of endometrial polyps in breast cancer patients treated with tamoxifen (nolvadex)]. Ivanova V; Karaivanov M; Raĭcheva S; Marinov E; Gorchev G Akush Ginekol (Sofiia); 2004; 43(2):33-6. PubMed ID: 15185527 [TBL] [Abstract][Full Text] [Related]
10. [Tamoxifen in breast cancer: viewpoint of the gynecologist]. De Muylder X Acta Clin Belg; 1992; 47(3):178-84. PubMed ID: 1332348 [TBL] [Abstract][Full Text] [Related]
11. Hypercalcaemia after tamoxifen for breast cancer: a sign of tumour response? Villalon AH; Tattersall MH; Fox RM; Woods RL Br Med J; 1979 Nov; 2(6201):1329-30. PubMed ID: 519433 [No Abstract] [Full Text] [Related]
12. Nephrotic syndrome and adjuvant treatment with tamoxifen for early breast cancer. Case report and review of the literature. Lauro S; Lalle M; D'Andrea MR; Vecchione A; Frati L Anticancer Res; 1994; 14(5B):2171-2. PubMed ID: 7840519 [TBL] [Abstract][Full Text] [Related]
13. Hypercalcaemia after tamoxifen for breast cancer. Rees GJ Br Med J; 1979 Dec; 2(6204):1590. PubMed ID: 534902 [No Abstract] [Full Text] [Related]
15. Tamoxifen and endometrial cancer. Jordan VC Lancet; 1988 Oct; 2(8618):1019. PubMed ID: 2902449 [No Abstract] [Full Text] [Related]
16. The Author's Response: Assessment of Breast Cancer Patients' Knowledge and Decisional Conflict Regarding Tamoxifen Use. Kim SI; Lim MC; Lee ES J Korean Med Sci; 2016 Apr; 31(4):647. PubMed ID: 27051254 [No Abstract] [Full Text] [Related]
17. [Breast cancer: can tamoxifen, under certain conditions, have adverse effects?]. Cosset JM; Burtin P Bull Cancer; 1991; 78(8):685-6. PubMed ID: 1932836 [No Abstract] [Full Text] [Related]
18. [Malignant mixed müllerian tumor of the uterus following tamoxifen for breast cancer: case report]. Saim M; Cote JF; Morel O; Malartic C; Akerman G; Gray F; Barranger E Gynecol Obstet Fertil; 2008 Feb; 36(2):166-168. PubMed ID: 18249575 [TBL] [Abstract][Full Text] [Related]
19. Tamoxifen-associated thromboembolism in breast cancer. Eroglu A Thromb Res; 2013 Jun; 131(6):566. PubMed ID: 22959707 [No Abstract] [Full Text] [Related]